Coronary Disease News and Research

RSS

Decreased release of neurotransmitter acetylcholine contributes to heart failure

Scientists at the Robarts Research Institute at The University of Western Ontario, working in collaboration with researchers in Brazil, have used a unique genetically-modified mouse line to reveal a previously unidentified mechanism contributing to heart failure.

2 Feb 2010

Majority of Americans agree monetary stress can negatively affect health

As we enter a new decade with the hope of rebounding from one of the worst economic downturns in our history, a newly commissioned bank study confirms that nearly 90 percent of Americans agree that monetary stress can negatively affect one’s health. Even more women (91 percent) and older adults (92 percent of those 45 and older) link stress to concerns over money.

28 Jan 2010

Researchers set on grand challenge to accomplish targeted drug delivery for heart disease

Virginia Tech researcher Pavlos Vlachos and his students in the College of Engineering have a tall order to tackle: Stem the grim progression of heart disease, which kills hundreds of thousands of people each year in the United States alone.

23 Jan 2010

Besides LDL, Lp(a) can also increase risk for heart disease

LDL isn't the only "bad boy" when it comes to cholesterol. According to a new study, a lipoprotein in the bloodstream called Lp(a) — pronounced "LP little A" — can be labeled "bad cholesterol."

20 Jan 2010

CSI receives authorization to begin its pivotal trial of ORBIT II

Cardiovascular Systems, Inc. (CSI), has received Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to evaluate the safety and effectiveness of its Diamondback 360® System in the treatment of calcified coronary lesions. With this conditional approval, CSI is authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites.

17 Jan 2010

NewCardio announces two encouraging validation studies related to CardioBip

NewCardio, Inc., a cardiac diagnostic technology provider, announced today two encouraging validation studies related to CardioBip(TM), a hand-held patient-activated device for recording and wireless transmission of reconstructed 12-lead ECGs.

6 Jan 2010

Volcano lauds revised guidelines for treating severe coronary artery disease patients

Volcano Corporation, a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, reacted positively to the new guidelines for treating coronary disease and heart attacks using percutaneous coronary intervention (PCI), a procedure that treats narrowed blood vessels.

23 Dec 2009

UCLA engineers and physicians develop PAD treatment device to prevent thrombosis

A fortuitous discovery that grew out of a collaboration between UCLA engineers and physicians could potentially offer hope to the nearly 10 million Americans who suffer from peripheral arterial disease.

26 Nov 2009

Drug therapy offers substantial cost savings than angioplasty

Many patients with diabetes should forego angioplasties for heart disease and just take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.

18 Nov 2009

New reversible oral anti-platelet medication had fewer cardiac events in heart attack patients

Acutely ill heart attack patients who received both aspirin and a new reversible oral anti-platelet medication had fewer cardiac events than patients on aspirin and the most commonly used, irreversible anti-platelet drug, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Exercise and lifestyle changes are key to improve heart health

Exercise is a wonderful way of boosting heart health, but it's proving to be a tough sell in Ontario South Asian communities, Dr. Milan Gupta told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

26 Oct 2009

RED Light energy drink aims to add more corporate accounts

In a market saturated with energy drinks and shots, entrepreneur Paul Ebrahimian knew he was in for a challenge when he founded RED Light(R). However, he had the recipe for a great-tasting beverage, a smart business plan in place and the marketing vision to position RED Light as THE drink of choice--not just for energy, but also as an elixir.

15 Sep 2009

Boston Scientific reports two-year data from SYNTAX clinical trial

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific (NYSE: BSX), has reported two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the Taxus(R) Express(R) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

SYNTAX clinical trial results announced

Boston Scientific Corporation (NYSE: BSX) today announced two-year data from its SYNTAX clinical trial comparing percutaneous coronary intervention (PCI) using the TAXUS((R)) Express((R)) Paclitaxel-Eluting Coronary Stent System to coronary artery bypass graft (CABG) surgery.

3 Sep 2009

Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study

For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain.

1 Sep 2009

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Boston Scientific Corporation today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

28 Aug 2009

New prostate cancer metastasis prediction method

Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis.

1 Jul 2009

Periodontitis and atherosclerotic cardiovascular disease

Additional research is called for and patients with moderate to severe periodontitis should receive evaluation and possible treatment to reduce their risk of atherosclerotic cardiovascular disease (CVD), according to a special consensus paper by editors of The American Journal of Cardiology and Journal of Peridontology in the July 1, 2009 issue of The American Journal of Cardiology, published by Elsevier.

30 Jun 2009

Telehealth interventions for the secondary prevention of coronary heart disease

The use of phone and internet between patients and healthcare providers is an effective way to reduce risk factors for coronary heart disease and the risk of further events after a heart attack, according to new research published today in the June issue of the European Journal of Cardiovascular Prevention & Rehabilitation.

16 Jun 2009

Diabetes with coronary disease: A moving target amid evolving therapies

In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."

8 Jun 2009